Ophthalmology

Latest News

money health | Image credit: utah51 - stock.adobe.com
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth

March 14th 2024

In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.

Eye on Pharma banner
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo

March 6th 2024

Elder Asian woman with eye care treatment | Image Credit: Chinnapong - stock.adobe.com
QL1207 Biosimilar Shows Equivalent Efficacy, Safety to Aflibercept in Treating nAMD

March 5th 2024

doctor talking to patient | Image credit: Prostock-studio - stock.adobe.com
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More

February 29th 2024

contract | Image credit: Pitchayaarch - stock.adobe.com
Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates

February 27th 2024

Video Interviews
Podcasts
"SEEING EYE TO EYE:  Exploring Different Perspectives on Ophthalmology Biosimilars SEEING EYE TO EYE:  Exploring Different Perspectives on Ophthalmology Biosimilars" with the CfB logo and an image of an eye
CfB podcast banner
CfB podcast banner
CfB podcast banner

More News

© 2024 MJH Life Sciences

All rights reserved.